NCT03407144 | Cancer Search

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

phase

Phase 2

status

Recruiting

enrollment

440

score

start date

2018-04-09

last updated

2021-12-29

biomarkers

N/A

conditions

Classical Hodgkin Lymphoma

drugs

bleomycin

cyclophosphamide

dacarbazine

doxorubicin

etoposide

pembrolizumab

prednisolone

prednisone

vinblastine

vincristine

primary contact

Toll Free Number

source

clinicaltrials.gov

New York City, New York

Columbia University/Herbert Irving Cancer Center ( Site 0063)

Weill Cornell Medicine ( Site 0032)

+1 more facilities

Los Angeles, California

Kaiser Permanente Downey Medical Center ( Site 0024)

Chicago, Illinois

University of Chicago ( Site 0066)

Houston, Texas

Texas Children's Hospital ( Site 0042)

Phoenix, Arizona

Phoenix Childrens Hospital ( Site 0034)

Dallas, Texas

Children's Medical Center ( Site 0030)

Austin, Texas

Dell Children's Medical Center Of Central Texas ( Site 0058)

Columbus, Ohio

Nationwide Children's Hospital ( Site 0037)

Indianapolis, Indiana

Riley Hospital for Children ( Site 0091)

Seattle, Washington

Seattle Childrens Hospital ( Site 0022)

Detroit, Michigan

Children's Hospital of Michigan ( Site 0056)

Karmanos Cancer Institute ( Site 0002)

Las Vegas, Nevada

Alliance for Childhood Diseases ( Site 0064)

60 sites
Page 1 of 5

Open Page 2